XenoPort to Release Second Quarter Financial Results on August 5, 2015

SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. Naprosyn (Naproxen) without Rx (Nasdaq:XNPT) announced today that it will release its second quarter financial results on August 5, 2015 at approximately 4:30 p.m. Buy Lamictal (Lamotrigine) without prescription Eastern Time. Evista (Raloxifene) without Rx The company will host a conference call at 5:00 p.m. About Donecept with no Rx Eastern Time that same day to provide a summary of its financial results and general business updates. Buy Tenormin (Atenolol) A replay of the call will be available for one week following the event. To access the conference call via the Internet, go to .XenoPort.com. Buy Vitamin K online Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required. To access the live conference call via phone, dial 1-888-275-3514. http://futurepharmaceuticals.wordpress.com International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 82478839. The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at .XenoPort.com, or via phone at 1-855-859-2056 for domestic callers, or 404-537-3406 for international callers. The reference number to enter the replay of the call is 82478839. About XenoPort XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. XenoPort is currently commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for patients with moderate-to-severe chronic plaque-type psoriasis and potentially for relapsing forms of multiple sclerosis. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort has entered into a collaboration with the National Institute on Alcohol Abuse and Alcoholism for the potential development of HORIZANT as a treatment for AUD and has granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Indivior PLC for all indications. XenoPort s pipeline of product candidates also includes a potential treatment for patients with idiopathic Parkinson s disease. HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc. XNPT2F